Lancet Gastroen Hepatol: Laparoscopic reenterocitis vs Inphyse saucytose rectum treatment of enteritis-type Crohn's disease

LIR! In the C trial, researchers compared the effects of laparoscopic reenterophtrual resection on the long-term quality of life of patients with Crohn's disease (CD), and the results were published recentlyin this retrospective follow-up study, the researchers collected participants in LIR! C study of patient data to examine factors that affect the effects of surgery, repeated surgery or anti-TNF treatment, and the duration of treatment, as well as the identification of factors associated with the duration of treatment effectsThe duration of the therapeutic effect is defined as the time that no additional Crohn's disease-related treatment (corticosteroids,immuno
regulators, biologics, or surgery is required)obtained long-term follow-up data for 134 patients, including 69 in the surgical excision group and 65 cases in the Inphyxix monotomareactor groupThe average follow-up time was 63.5 monthsEighteen (26%) of the 69 patients in the excision group started anti-TNF therapy without the need for a second excisionTwenty-nine (42%) patients in the excision group did not require additional Crohn's disease-related medication, although 14 (48%) of them were treated withpreventiveimmunomodulatorsThirty-one (48%) of the 65 patients in the Inphyxisia sepsis group underwent Crohn's disease-related excision, and the remaining 34 patients maintained, converted or strengthened anti-TNF treatmentThe duration of treatment was similar, with the median duration of treatment without additional Crohn's disease in the excision group was 33.0 months and the inflixil monobitinous group was 34.0 monthsIn both groups, the treatment of immunomodulators was associated with the duration of the therapeutic effect, except for the assigned treatment (the risk ratio was 0.34 in the excision group and 0.49 in the inflixil monotophobic group)studies support the use of laparoscopic reenteroctomy as a treatment option for Crohn's disease, especially for patients with limited limitations (subject to reactive sections of 40 cm) and inflammatory end-of-reenteritis, with routine treatment not successful